Pipeline
The Augustus Therapeutics pipeline is built around a differentiated, multi-modality approach to oncology, combining precision small molecules, engineered CAR-T cell therapies, and oncolytic virus platforms. By addressing tumor-intrinsic vulnerabilities and harnessing the immune system’s capacity to recognize and eliminate cancer, we aim to develop durable, targeted treatments for patients with difficult-to-treat and treatment-resistant cancers.
Program
Discovery
Lead Optimization
Pre Clinical
Phase 1
HT-09
Immunomodulatory Peptides
HT-09 is a proprietary peptide developed to address one of the most critical unmet needs in modern cancer immunotherapy: the generation and maintenance of durable, long-lived immune responses.
GOLDEN
Immunotherapy
A novel immune-therapeutic technology.
Stage Complete
Upcoming
Want to learn more about our programs?
- Precision-Driven Research
- Innovative Cancer Therapies
- Science-Led Solutions